Published in

American Association of Immunologists, The Journal of Immunology, 9(182), p. 5203-5207, 2009

DOI: 10.4049/jimmunol.0804243

Links

Tools

Export citation

Search in Google Scholar

CD59 Blockade Enhances Antigen-Specific CD4+ T Cell Responses in Humans: A New Target for Cancer Immunotherapy?

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Red circle
Postprint: archiving forbidden
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

CD59, a broadly expressed GPI anchored molecule, regulates formation of the membrane attack complex of the complement cascade. We previously demonstrated that mouse CD59 also down-modulates CD4+ T cell activity in vivo. In this study, we explored the role of CD59 on human CD4+ T cells. Our data demonstrate that CD59 is up regulated on activated CD4+ T cells and serves to down-modulate their activity in response to polyclonal and antigen- specific stimulation. The therapeutic potential of this finding was explored using T cells isolated from colorectal cancer patients. The findings were striking and indicated that blockade of CD59 significantly enhanced the CD4+ T cell response to two different tumor antigens. These data highlight the potential for manipulating CD59 expression on T cells for boosting weak immune responses, such as those found in individuals with cancer.